|
 The delays are expected to be resolved soon and will not impact
monthly delivery targets, the company said, adding it was aiming to
deliver 300 million doses by the end of July, instead of September
end.
Moderna expects to deliver an average of 30 million to 35 million
doses a month in February and March and 40 million to 50 million
doses every month from April to July end.
The United States, which is fighting supply constraints in its
large-scale efforts to vaccinate its population, earlier this month
bought an additional 100 million vaccine doses from Moderna, taking
the total ordered doses to 300 million.
The biotech firm reiterated it was on track to deliver the first
batch of 100 million doses by the end of March and was moving
forward the supply target for the second batch by a month to May
end.
[to top of second column] |
 Meanwhile, Catalent said in an
email statement it is meeting all its vaccine
production commitments, including Moderna's goal
of 100-million doses by the end of March. The
firm signed an agreement last year to help fill
and package vials with Moderna vaccine.
The U.S. government has so far administered
about 25.5 million doses of the two-dose
vaccine, with 45.4 million doses supplied,
Moderna said.
An additional 33.2 million doses have been
filled in vials and are at various stages of
final production and testing before release to
the U.S. government, the company said.
(Reporting by Manojna Maddipatla and Ankur
Banerjee in Bengaluru; Editing by Shounak
Dasgupta and Arun Koyyur)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
